KDS 1000
Alternative Names: KDS-1000Latest Information Update: 02 Oct 2021
At a glance
- Originator Kiadis
- Class Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 24 Aug 2021 Kiadis Pharma withdraws prior to enrolment a phase I/II trial for COVID-2019 infections (Parenteral) (NCT04797975)
- 19 Mar 2021 Abigail Wexner Research Institute has a patent pending for a novel therapeutic, “universal donor” NK cells, to restore the patients’ NK cell numbers in USA
- 15 Mar 2021 Kiadis Pharma in-licenses technology and intellectual property related to NK cells technology from Abigail Wexner Research Institute for treatment of COVID-2019 infections